|
|
 |
|
Viewing report
|
|
|
|
Liver Cancer Drugs - Global Strategic Business Report
Global Industry Analysts, Inc., April 2010, Pages: 506
This report analyzes the Global market for Liver Cancer Drugs in US$ Million.
Annual estimates and forecasts are provided for the period 2007 through 2015.
The report profiles 40 companies including 4SC AG, Actavis Group, Inc., Alnylam Pharmaceuticals, Inc., ArQule, Inc., Bayer Schering Pharma AG, Bristol-Myers Squibb Company, Celsion Corp, Eli Lilly & Company, ImClone Systems Inc., F. Hoffmann–La Roche Ltd., Jennerex Biotherapeutics, Inc., Onyx Pharmaceuticals, Inc., Pfizer Inc., Progen Pharmaceuticals Ltd., and Teva Pharmaceutical Industries Ltd.
Market data and analytics are derived from primary and secondary research.
Company profiles are mostly extracted from URL research and reported select online sources.
Please note: Reports are sold as single-site single-user licenses. The delivery time for hard copies is between 3-5 business days, as each hard copy is custom printed for the organization ordering it. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks.
For information on site licence pricing please click on Enquire before buying
Customers who bought this item also bought
ThermoDox - Analysis and Market Forecasts from 2012 to 2020
Liver Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2017
Stakeholder Opinions: Hepatocellular cancer
Competitor Analysis: Ras-Raf-MEK-ERK Inhibitors
Liver Cancer - Pipeline Review, Q1 2011
Angiogenesis Inhibitors and Stimulators - Global Strategic Business Report
Small Molecule Kinase Inhibitors - Global Strategic Business Report
Pipeline Insight: Gastrointestinal Cancer Overview - Metastatic gastrointestinal cancers represent a significant commercial opportunity due to a lack of approved drugs
Drug Delivery in Cancer - Technologies, Markets and Companies
Hepatocellular Carcinoma - Pipeline Review, H1 2012
|
|
|
|
